View in EDS HTML Full Text PDF Full Text

Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T.

Saved in:
Bibliographic Details
Title: Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T.
Authors: Gustine JN; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Attar N; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Puliafito BR; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Cirstea DD; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Branagan AR; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Yee AJ; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA., Raje NS; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA. nraje@mgh.harvard.edu.
Source: Blood cancer journal [Blood Cancer J] 2026 Apr 22; Vol. 16 (1). Date of Electronic Publication: 2026 Apr 22.
Publication Type: Journal Article
Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42020379
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gustine+JN%22">Gustine JN</searchLink>; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Attar+N%22">Attar N</searchLink>; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Puliafito+BR%22">Puliafito BR</searchLink>; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Cirstea+DD%22">Cirstea DD</searchLink>; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Branagan+AR%22">Branagan AR</searchLink>; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Yee+AJ%22">Yee AJ</searchLink>; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Raje+NS%22">Raje NS</searchLink>; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA. nraje@mgh.harvard.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568469%22">Blood cancer journal</searchLink> [Blood Cancer J] 2026 Apr 22; Vol. 16 (1). <i>Date of Electronic Publication: </i>2026 Apr 22.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101568469 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2044-5385 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220445385%22">20445385 </searchLink><i>NLM ISO Abbreviation: </i>Blood Cancer J <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42020379
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41408-026-01510-1
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gustine JN
      – PersonEntity:
          Name:
            NameFull: Attar N
      – PersonEntity:
          Name:
            NameFull: Puliafito BR
      – PersonEntity:
          Name:
            NameFull: Cirstea DD
      – PersonEntity:
          Name:
            NameFull: Branagan AR
      – PersonEntity:
          Name:
            NameFull: Yee AJ
      – PersonEntity:
          Name:
            NameFull: Raje NS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 22
              M: 04
              Text: 2026 Apr 22
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2044-5385
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Blood cancer journal
              Type: main
ResultId 1